Soleno Therapeutics (NASDAQ:SLNO) focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company's flagship project includes its efforts to tackle Prader-Willi Syndrome, a genetic disorder characterized by obesity, intellectual disability, and shortness in stature, among other symptoms. Soleno Therapeutics is dedicated to improving patient outcomes and addressing unmet medical needs within the rare disease community. Through ongoing research and development, the company aims to expand its portfolio and bring innovative treatments to market, demonstrating its commitment to enhancing the lives of those affected by rare conditions.